RecruitingOBSERVATIONAL

Study and Follow-up of Multiple Endocrine Neoplasia Type 1

This study is gathering information from people in France who have a rare condition called Multiple Endocrine Neoplasia Type 1 (MEN1). This condition can lead to growths, usually not cancerous, in different glands like the parathyroid, pancreas, and pituitary. Even though doctors have known about MEN1 for a long time, we still don't fully understand how it affects people over time or the very best ways to treat it. The study plans to collect information over many years to get a clearer picture of MEN1. By doing this, researchers hope to improve how the condition is diagnosed, monitored, and treated, ultimately helping patients and their families live healthier lives.

At a glance

Status

Recruiting

Sponsor

Centre Hospitalier Universitaire Dijon

Enrolment target

2,000

Start

01 Jul 2012

Estimated completion

01 Jul 2031

Multiple Endocrine Neoplasia

What is this study about?

This study is looking at a rare inherited condition called Multiple Endocrine Neoplasia Type 1, or MEN1. It means that people with this condition have a higher chance of developing growths, which are often not cancerous, in certain glands in their body. These growths most commonly affect the parathyroid glands (which control calcium levels), the pancreas (which helps with digestion and blood sugar), and the pituitary gland (a master gland in the brain). Other parts of the body can also be affected.

While MEN1 has been known for many years, doctors still don't have a complete understanding of how it develops over a person's lifetime or the best ways to manage all its different aspects. Current research on MEN1 is often based on small groups of people, and this makes it hard to give clear answers to all the questions patients and doctors have. This study aims to change that by collecting information from a larger group of people with MEN1 over a long period.

The main goal is to get a much clearer picture of how MEN1 affects people. This will help doctors better understand the disease, improve how they find it early, decide on the best treatments, and manage the condition to help people live better and longer lives. It also helps families by screening relatives who might also have the condition, even if they don't have symptoms yet.

Key takeaways

The study aims to improve understanding of a rare condition called MEN1.
It focuses on people with MEN1 in France.
No new treatments are given; it's an observational follow-up study.
Participation helps scientists learn how MEN1 affects people over time.
The goal is better diagnosis and management for MEN1 patients in the future.

Who may be eligible?

This study is specifically looking for people living in France who have received a confirmed diagnosis of MEN1. This includes individuals who are experiencing symptoms related to the condition.

You might also be able to join if you have at least two of the main problems associated with MEN1 (like parathyroid, pancreas, or pituitary growths). Or, if you have one known growth, whether it's one of the main ones or another related type (like adrenal or thymus), and it's linked to a specific change in your genes (called a MEN1 gene mutation). You could also be eligible if you have one known growth and someone in your close family has been diagnosed with MEN1.

Even if you don't have symptoms yet but have a known MEN1 gene mutation, you might be able to participate. This is because it's understood that people with this mutation will likely develop symptoms later on. However, you can't join if your condition is a single-gland problem that's part of another specific genetic syndrome, such as familial isolated pituitary adenoma (FIPA) or familial isolated hyperparathyroidism (FIHP).

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Do you live in France?
Have you been officially diagnosed with MEN1?
Do you have at least two of the main MEN1-related growths (parathyroid, pancreas, pituitary)?
Or do you have a known MEN1 gene change (mutation)?
Or does a close family member have MEN1, and you have a related growth?
Is your condition not part of another specific single-gland genetic syndrome?

Answer every question to see your result.

What does participation involve?

Taking part in this study means you would be involved in a long-term follow-up survey. This typically involves sharing information about your health over time. There are no new medications or special treatments given as part of this study. Instead, researchers will be collecting information about your usual care, how your MEN1 develops, and any treatments you receive. The exact schedule for providing information would be explained by the study team, but it's focused on understanding how your condition progresses over many years.

Potential risks and benefits

There are no significant physical risks involved in this study as it doesn't involve new medicines or treatments; it's mainly about collecting information. However, you might find it time-consuming to provide your medical details. The potential benefit is that your participation will help doctors and researchers understand MEN1 much better, which could lead to improved diagnosis and treatment for future patients and potentially for you. You are free to stop participating at any time without giving a reason, and this will not affect your medical care.

Locations (1)

CHU Dijon Bourgogne
Verified postcode
Dijon, France· Recruiting

Common questions

What is MEN1?

MEN1 is a rare genetic condition where people are more likely to develop growths, often not cancerous, in certain glands like the parathyroid, pancreas, and pituitary.

Why is this study important?

This study helps doctors learn more about how MEN1 develops over time and find better ways to diagnose and treat it, as current information is limited.

Do I have to take new medicine in this study?

No, this study does not involve any new medicines or treatments. It's about collecting information on how your condition is managed over time.

Can my family members also join?

The study is looking at people with confirmed MEN1. If family members have also been diagnosed, they might be eligible.

What happens to the information I provide?

The information you share will be used by researchers to understand MEN1 better, always protecting your privacy.

How to find out more

Pierre GOUDET, MD

pierre.goudet@chu-dijon.fr 380293031 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.